BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat

Phase 1

Completed

Conditions: Human Immunodeficiency Virus Type 1 (HIV-1)

Interventions: Drug: Atazanavir/Cobicistat FDC
Drug: Atazanavir
Drug: Cobicistat

First Posted Date: 2013-04-23

Last Posted Date: 2014-08-29

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 64

Registration Number: NCT01837719

Locations: 🇺🇸
Ppd Development, Inc., Austin, Texas, United States

Efficacy, Safety, Pharmacokinetics and Immunogenicity Study of Abatacept Administered Intravenously to Treat Active Polyarticular-course Juvenile Idiopathic Arthritis in Japan

Phase 3

Completed

Conditions: Juvenile Idiopathic Arthritis

Interventions: Drug: Abatacept

First Posted Date: 2013-04-19

Last Posted Date: 2021-02-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 23

Registration Number: NCT01835470

Locations: 🇯🇵
Local Institution, Shinjuku-ku, Tokyo, Japan

Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment

Phase 1

Completed

Conditions: Hepatitis C

Interventions: Drug: Daclatasvir

First Posted Date: 2013-04-12

Last Posted Date: 2015-11-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 58

Registration Number: NCT01830205

Locations: 🇺🇸
Davita Clinical Research, Minneapolis, Minnesota, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based

Phase 3

Completed

Conditions: Kidney Transplantation

Interventions: Drug: Tacrolimus
Drug: Belatacept
Drug: Cyclosporine

First Posted Date: 2013-03-29

Last Posted Date: 2021-01-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 446

Registration Number: NCT01820572

Locations: 🇺🇸
Transplant Research Institute (PI Address), Los Angeles, California, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Saint Barnabas Medical Center, Livingston, New Jersey, United States

and more 59 locations

Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve Patients

Phase 3

Withdrawn

Conditions: Hepatitis C

Interventions: Drug: Peginterferon alfa 2a
Drug: Ribavirin
Drug: Placebo matching Daclatasvir
Drug: Daclatasvir

First Posted Date: 2013-02-25

Last Posted Date: 2013-11-25

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT01797848

Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin

Phase 2

Completed

Conditions: Hepatitis C

Interventions: Biological: Pegylated Interferon Lambda
Drug: Ribasphere
Drug: Daclatasvir

First Posted Date: 2013-02-21

Last Posted Date: 2015-10-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 165

Registration Number: NCT01795911

Locations: 🇺🇸
Alamo Medical Research, San Antonio, Texas, United States

Pharmacokinetics, Safety and Tolerability of Single-dose Belatacept in Adolescent Kidney Transplant Recipients

Phase 2

Completed

Conditions: Kidney Transplant

Interventions: Drug: Belatacept

First Posted Date: 2013-02-15

Last Posted Date: 2017-07-24

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 16

Registration Number: NCT01791491

Locations: 🇺🇸
Boston Childrens Hospital, Boston, Massachusetts, United States
🇺🇸
University Of Alabama At Birmingham, Birmingham, Alabama, United States
🇺🇸
Childrens Hospital Of La, Los Angeles, California, United States

and more 5 locations

Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)

Phase 2

Completed

Conditions: Advanced or Metastatic Melanoma

Interventions: Biological: Nivolumab
Biological: Ipilimumab

First Posted Date: 2013-02-05

Last Posted Date: 2021-08-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 138

Registration Number: NCT01783938

Locations: 🇺🇸
University Of Virginia Health System, Charlottesville, Virginia, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

and more 7 locations

Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma

Phase 1

Completed

Conditions: B-Cell Malignancies

Interventions: Biological: Urelumab
Biological: Rituximab

First Posted Date: 2013-01-25

Last Posted Date: 2017-03-31

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 47

Registration Number: NCT01775631

Locations: 🇺🇸
Ucla Department Of Medicine, Los Angeles, California, United States
🇺🇸
John Theurer Cancer Center, Hackensack, New Jersey, United States
🇺🇸
The University Of Texas Md Anderson Cancer Center, Houston, Texas, United States

and more 12 locations

Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers

Phase 4

Completed

Conditions: Transplant Rejection

Interventions: Drug: Caffeine
Drug: Losartan
Drug: Omeprazole
Drug: Dextromethorphan
Drug: Midazolam
Biological: Belatacept

First Posted Date: 2013-01-11

Last Posted Date: 2014-06-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 45

Registration Number: NCT01766050

Locations: 🇺🇸
Healthcare Discoveries, Llc D/B/A Icon Development Solutions, San Antonio, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy